Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Davunetide Granted Orphan Drug Status

By Drug Discovery Trends Editor | March 18, 2010

Allon Therapeutics Inc. announced that its lead neuroprotective drug candidate, davunetide, has been granted Orphan Drug Status in the European Union (EU) for the treatment of Progressive Supranuclear Palsy (PSP), a rapidly progressing and fatal degenerative brain disease. Allon announced on January 12, 2010 that the U.S. Food and Drug Administration granted davunetide Orphan Drug Status for PSP treatment in the United States.

Gordon McCauley, President and CEO of Allon, said the EU designation extends both the scientific validation and the potential market for davunetide as a treatment for PSP as well as other degenerative brain diseases with similar pathologies. “Extending davunetide’s potential use in the area of PSP is a significant business opportunity for Allon, made even more attractive by achieving Orphan Drug Designation in the world’s two largest pharmaceutical markets, the U.S. and the EU,” said McCauley. “Allon has demonstrated a strong scientific and clinical rationale for the potential efficacy of davunetide in PSP. The pathology of PSP and Alzheimer’s is similar in that both diseases involve impairment of the brain protein tau. Our clinical trial program is focused on confirming davunetide’s potential to be the first approved treatment for PSP and other brain diseases involving tau impairment.”

Research has shown that davunetide reduced tau impairment and preserved memory in mice bred to replicate Alzheimer’s or PSP tau pathology. In addition, Phase 2 clinical trials have shown that davunetide can also improve memory function in patients with amnestic mild cognitive impairment (aMCI), a precursor to Alzheimer’s disease in which a primary neuropathology involves tau.

“We are pleased to have reached this important milestone and look forward to working with the European regulators as we plan and begin the European portion of our upcoming PSP clinical trial,” said McCauley.

Allon announced January 26, 2010 that the clinical trial program for PSP is commencing with a pilot clinical trial in the U.S. sponsored by the Memory and Aging Center of the University of California, San Francisco (UCSF). This pilot clinical study, enrolling approximately 12 patients, will help Allon and its clinical collaborators validate the trial design and prepare for a larger multinational Phase 2 PSP clinical trial scheduled to begin this year.

Trial investigators are among the leading experts in the field, including Drs. Bruce Miller and Adam Boxer of the UCSF Memory and Aging Center.

On March 11, 2010, Allon announced it had completed a Phase 1 clinical trial that broadened the demonstrated safety and dose range of davunetide. Davunetide has already shown human efficacy and safety in clinical trials with daily doses of 5 mg and 30 mg. The new trial evaluated the drug’s safety and pharmacokinetic profile at doses up to 60 mg per day.

Date: March 17, 2010
Source: Allon Therapeutics Inc.


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE